184 related articles for article (PubMed ID: 25766456)
1. Feedback for patients reporting adverse drug reactions; satisfaction and expectations.
Rolfes L; van Hunsel F; van Grootheest K; van Puijenbroek E
Expert Opin Drug Saf; 2015 May; 14(5):625-32. PubMed ID: 25766456
[TBL] [Abstract][Full Text] [Related]
2. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands.
Oosterhuis I; van Hunsel FP; van Puijenbroek EP
Drug Saf; 2012 Mar; 35(3):221-32. PubMed ID: 22201474
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
5. Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.
Sabblah GT; Darko DM; Mogtari H; Härmark L; van Puijenbroek E
Drug Saf; 2017 Oct; 40(10):911-921. PubMed ID: 28653291
[TBL] [Abstract][Full Text] [Related]
6. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Experiencing Adverse Drug Reactions on the Patient's Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands.
Rolfes L; van Hunsel F; Taxis K; van Puijenbroek E
Drug Saf; 2016 Aug; 39(8):769-76. PubMed ID: 27145946
[TBL] [Abstract][Full Text] [Related]
8. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
Jarernsiripornkul N; Patsuree A; Krska J
Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
[TBL] [Abstract][Full Text] [Related]
9. [Satisfaction of a pharmacovigilance declaration support network in general practice].
Driot D; Figuet L; Birebent J; Coste S; Durrieu G; Jacquot J; Bismuth M
Therapie; 2018 Dec; 73(6):483-493. PubMed ID: 29921459
[TBL] [Abstract][Full Text] [Related]
10. Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana.
Sabblah GT; Darko D; Härmark L; van Puijenbroek E
Ghana Med J; 2019 Jun; 53(2):150-155. PubMed ID: 31481811
[TBL] [Abstract][Full Text] [Related]
11. Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD.
Weits G; Härmark L; Hartman J; Kant A
Expert Opin Drug Saf; 2019 Apr; 18(4):333-337. PubMed ID: 30845849
[TBL] [Abstract][Full Text] [Related]
12. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
13. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.
van Hunsel F; van der Welle C; Passier A; van Puijenbroek E; van Grootheest K
Eur J Clin Pharmacol; 2010 Nov; 66(11):1143-50. PubMed ID: 20658130
[TBL] [Abstract][Full Text] [Related]
14. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction.
Cornelissen L; van Puijenbroek E; van Grootheest K
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):76-81. PubMed ID: 17987591
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
16. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of etifoxine: A French pharmacovigilance survey.
Cottin J; Gouraud A; Jean-Pastor MJ; Dautriche AD; Boulay C; Geniaux H; Auffret M; Bernard N; Descotes J; Vial T
Fundam Clin Pharmacol; 2016 Apr; 30(2):147-52. PubMed ID: 26588183
[TBL] [Abstract][Full Text] [Related]
18. Founding an adverse drug reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a general hospital.
Goldstein LH; Berlin M; Saliba W; Elias M; Berkovitch M
J Clin Pharmacol; 2013 Nov; 53(11):1220-5. PubMed ID: 23852627
[TBL] [Abstract][Full Text] [Related]
19. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal.
Santosh KC; Tragulpiankit P; Edwards IR; Gorsanan S
Int J Risk Saf Med; 2013 Jan; 25(1):1-16. PubMed ID: 23442293
[TBL] [Abstract][Full Text] [Related]
20. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
